Intrathecal Tyr-W-MIF-1 produces potent, naloxone-reversible analgesia modulated by α2-adrenoceptors

European Journal of Pharmacology

Volumn 298, Issue 3, 1996, Pages 235-239

  Gergen, Kerra A ^a   Zadina, James E ^a,c   Kastin, Abba J ^a   Paul, Dennis ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Analgesia; Desipramine; Neuropeptide; Spinal cord; 2 Adrenoceptor; Opioid receptor

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA FUNALTREXAMINE; DESIPRAMINE; MELANOSTATIN DERIVATIVE; MU 1 OPIATE RECEPTOR ANTAGONIST; MU 2 OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NALOXONAZINE; NALOXONE; NEUROPEPTIDE; NORADRENERGIC RECEPTOR BLOCKING AGENT; TETRAPEPTIDE; TYROSYLPROLYLTRYPTOPHYLGLYCINAMIDE; UNCLASSIFIED DRUG; YOHIMBINE;

ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; INTRATHECAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; SPINAL CORD; SUBCUTANEOUS DRUG ADMINISTRATION; TAIL FLICK TEST;

EID: 0029919835     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(95)00823-3     Document Type: Article

References (26)

1. Camarata, P.J. and T.L. Yaksh, 1985, Characterization of the spinal adrenergic receptors mediating the spinal effects produced by micro-injection of morphine into the periaqueductal gray, Brain Res. 336, 133.
2. D'Amour, F.E. and D.L. Smith, 1941, A method for determining loss of pain sensation, J. Pharmacol. Exp. Ther. 72, 74.
3. 2 (Tyr-W-MIF-1), Peptides 13, 623.
4. 2), Peptides 15, 1505.
5. 2 sites in the guinea pig ileum, Neurosci. Lett. 39, 51.
6. Hackler, L., A.J. Kastin, J. Erchegyi and J.E. Zadina, 1993, Isolation of Tyr-W-MIF-1 from bovine hypothalami, Neuropeptides 24, 159.
7. Heyman, J.S., C.L. Williams, T.F. Burks, H.I. Mosberg and F. Porreca, 1988, Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine, J. Pharmacol. Exp. Ther. 245, 238.
8. Hylden, J.L.K. and G.L. Wilcox, 1980, Intrathecal morphine in mice: a new technique, Eur. J. Pharmacol. 67, 313.
9. Hylden, J.L.K. and G.L. Wilcox, 1983, Pharmacological characterization of substance P-induced nociception in mice: modulation by opioid and noradrenergic agonists at the spinal level, J. Pharmacol. Exp. Ther. 226, 398.
10. Jensen, T.S. and T.L. Yaksh, 1986, Examination of spinal monoamine receptors through which brainstem opiate-sensitive systems act in the rat, Brain Res. 363, 114.
11. Larsen, J.-J. and J. Arnt, 1984, Spinal 5-HT or NA uptake inhibition potentiates supraspinal morphine antinociception in rats, Acta Pharmacol. Toxicol. 54, 72.
12. Ling, G.S.F., R. Simantov, J.A. Clark and G.W. Pasternak, 1986, Naloxonazine actions in vivo, Eur. J. Pharmacol. 129, 33.
13. Lord, J.A.H., A.A. Waterfield, J. Hughes and H.W. Kosterlitz, 1977, Endogenous opioid peptides: multiple agonists and receptors, Nature 267, 495.
14. Paul, D. and P.J. Hornby, 1995, Potentiation of intrathecal DAMGO antinociception, but not gastrointestinal transit inhibition, by 5-hydroxytryptamine and norepinephrine uptake blockade, Life Sci. 56, PL 83.
15. Paul, D., R.J. Bodnar, M.A. Gistrak and G.W. Pasternak, 1989, Different mu receptor subtypes mediate spinal and supraspinal analgesia in mice, Eur. J. Pharmacol. 168, 307.
16. 2 opioid actions, Life Sci. 48, 2005.
17. Recht, L.D. and G.W. Pasternak, 1987, Effects of β-funaltrexamine on radiolabeled opioid binding, Eur. J. Pharmacol. 230, 341.
18. Reed, G.W., G.A. Olson and R.D. Olson, 1994, The Tyr-MIF-1 family of peptides, Neurosci. Biobehav. Rev. 18, 519.
19. 2-Adrenoceptor modulation of nociception in rat spinal cord: Location, effects and interactions with morphine, Eur. J. Pharmacol. 138, 169.
20. Ward, S.J. and A.E. Takemori, 1983, Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice, J. Pharmacol. Exp. Ther. 224, 525.
21. Ward, S.J., P.S. Portoghese and A.E. Takemori, 1982, Pharmacological characterization in vivo of the novel opiate, β-funaltrexamine, J. Pharmacol. Exp. Ther. 220, 494.
22. Wigdor, S. and G.L. Wilcox, 1987, Central and systemic morphine-induced antinociception in mice: contribution of descending serotonergic and noradrenergic pathways, J. Pharmacol. Exp. Ther. 242, 90.
23. Zadina, J.E., A.J. Kastin, L.-J. Ge and V. Brantl, 1990, Hemorphins, cytochrophins and human beta-casomorphins bind to antiopiate (Tyr-MIF-1) as well as opiate binding sites in the rat brain. Life Sci. 47, PL 25.
24. 2), Neurosci. Lett. 155, 220.
25. Zadina, J.E., A.J. Kastin, L.-J. Ge and L. Hackler, 1994a, Mu, delta and kappa opiate receptor binding of Tyr-MIF-1 and Tyr-W-MIF-1, its active fragments and two potent analogs. Life Sci. 55, PL 461.
26. Zadina, J.E., A.J. Kastin, L. Hackler and S.L. Chang, 1994b, Cyclic analogues of Tyr-W-MIF-1 with prolonged analgesic activity and potency comparable to DAMGO and morphine, Peptides 15, 1567.